Renerve Limited · ASX:RNV
Renerve — Shareholder Meeting (October 2026)
24 slides from Renerve's shareholder meeting presentation, Oct 5, 2026
Slide 1: Transforming Nerve Repair Through Science
ASX:RNV Transforming Nerve Repair Through Science ReNerve Company presentation Annual General Meeting | October 2026
Slide 2: Important Notice & Disclaimer
Important Notice & Disclaimer Nature of Document: This presentation has been prepared and issued by ReNerve Ltd Disclaimer: No representation or warranty, express or implied, is made by the Company that (Company) to provide general information about the Company. The information in this the material
Slide 3: Executive Summary
Executive Summary Summary Development of Novel Expanding Strong Sales & Nerve Repair & Product Portfolio Distribution Presence Regeneration Products 3 product ranges in the US market with more coming in 2026 to 2029 ReNerve has established logistics, ReNerve is developing a comprehensive warehouse a
Slide 4: Company Portfolio
Company Portfolio Product Product Commercial On Market R&D Development Development Nerve Cuff Nerve Tube Nerve Protector Nerve Guide Matrix Nerve Cap Dermal Tissue AmnioLite AmnioDuo Placental ReNerve Company presentation | October 2026 4
Slide 5: Quarter highlights
Quarter highlights ReNerve Quarterly Sales ‘23 to ‘26 Annual revenue 88% $240,000.00 up $220,000.00 $200,000.00 $180,000.00 Quarterly Sales (AUD) Revenue up >50% $160,000.00 $140,000.00 Compared to the previous qtr $120,000.00 $100,000.00 30th of June $80,000.00 Cash of $60,000.00 $1.48M $40,000.00
Slide 6: Commercial Business
ReNerve™ Commerci Business
Slide 7: Target Market
Target 2031 Market USD$6.0Bn USD$6.19Bn The Global Nerve Repair Biomaterials Market is projected to grow at a compound annual growth rate (CAGR) of 17.8% from 2024 to 2031 to USD$6.19Bn. Our Target Markets Global Nerve Repair Biomaterial Market Dermal and Amniotic Tissue 2025 Surgical Applications (
Slide 8: Global Nerve Repair Biomaterial Market
Global Global Nerve Repair Biomaterial Market Global Market by Segment $8.0Bn Nerve Repair $6.0Bn 32% 16% Biomaterial Market $4.0Bn USD $Bn $2.0Bn 52% - Nerve Wrap 2024 2025 2026 2027 2028 2029 2030 2031 Nerve Conduit North America Europe Nerve Grafts USD$1.69Bn ~900k Nerve Compression The Global Ne
Slide 9: Sales and Marketing Update
Sales and Marketing Update Robust Portfolio 25 distributors In the US 2 direct salespeople Ongoing new approvals All approvals designed to add additional US Market Expanded SKUs Distribution Channels All call points use all ReNerve products Focus surgical areas Subspecialties Hand Breast Lower Extre
Slide 10: Asia
Asia Hong Kong India • Significant opportunity • Strong local partner • Existing distribution partner in • Had initial orders and sales place last quarter • Surgeon and hospital • Now engaging with the local engagement already underway market Philippines Malaysia • Complements rest of Asia • Clear t
Slide 11: Nerve Cuff
Wound Care Overview and Information Nerve Cuff RN-SM-TRN-012 Rev.0
Slide 12: Key Features
Key Features ReNerve’s “Align” 1 Product • Protects nerves during recovery post peripheral nerve Clinical Study repair • Great handling characteristics and absorbed within 6 Patient Results months 2 Definitive clinical study on using NervAlign Nerve Patient Benefit Cuff for nerve repair 120 patients
Slide 13: The "Align" Study
The “Align” Study Clinical Study on the NervAlign® Nerve Cuff Undertaking a definitive study in nerve repair following surgical neurolysis to show the benefit of protecting the nerve post nerve Comparison of Patient Pre & Post repair surgery. Surgery Pain Score 7.1 7.1 Study Design: Two patient coho
Slide 14: Product Range
Wound Care Overview and Information Product Range RN-SM-TRN-012 Rev.0
Slide 15: Empliq Product Portfolio
Empliq Product Portfolio Empliq AmnioLite Empliq AmnioDuo Empliq Placental Empliq Dermal Description Single-layer amniotic membrane Double-layer amniotic membrane Placental allograft including amniotic Deep-layer dermal matrix allograft allograft membrane and chorion Clinical Value Natural barrier t
Slide 16: Development Programs
ReNerve™ peverctiealiee Programs
Slide 17: Product Development Pipeline
Product Development Pipeline Nerve Conduit and protector ranges Nerve ● Includes the Nerve cap conduit range ● Significant scale manufacturing ongoing ● 3 types of conduits to come to market In the commercial development Stage 3 of 4 FDA approval pathway confirmed Nerve guide matrix Next step GMP, c
Slide 18: R&D Programs
ria \ | St ReNerve™ : >— y a Za 5 R&D Programs
Slide 19: Exploratory Enhancement of Nerve Growth
R&D programs | Exploratory Enhancement of Nerve Growth Collaboration with RMIT with Partners include: Urologist and Colorectal Surgeon AEA grant funding Research Context Experimental Approach ● PRPs have been widely used “clinically” including as Injections • Isolated Platelet Rich Plasma will be ad
Slide 20: Exploratory Enhancement of Nerve Growth
R&D programs | Exploratory Enhancement of Nerve Growth Exosomes Partnership with Vivazome Research Context ● Exosomes are membrane-bound vesicles released by cells including stem cells ● Exosomes carry reparative molecules (eg mRNA’s, growth factors) ● Exosomes impact behaviour of other cells, inclu
Slide 21: Value Drivers for the next 12 to 36 Months
Value Drivers for Building out the Big jumps in sales and revenue product portfolio the next 12 to 36 Two main drivers: Months ● No expansion of the Empliq range required ● Empliq – will drive rapid sales ● All R&D focused on nerve repair growth products ● New products to expand nerve ● A full portf
Slide 22: Company Portfolio 2029 – with R&D ongoing
Company Portfolio 2029 – with R&D ongoing Product R&D Product Development Commercial Development On Market Nerve Cuff Nerve Tube Nerve Protector Nerve Guide Matrix Nerve Cap Nerve stimulator Nerve PRP program Nerve Exosomes Dermal Tissue AmnioLite AmnioDuo Placental ReNerve Company presentation | Oc
Slide 23: Executive Summary ReNerve Milestones
Executive Summary ReNerve Milestones Continued focus on sales expansion with first direct sales reps now full-time Nerve conduits, nerve guide matrix, nerve caps, nerves stimulators Building a portfolio of offerings into the market to expand revenue streams and able to ‘bundle’ into hospitals Using
Slide 24: Contact Us
ReNerve Company presentation | October 2026 Contact Us ReNerve Limited +61 (03) 9482 3940 info@renerve.com.au Level 10/99 Queen St, Melbourne, Victoria 3000 Australia Follow us on socials!